Preliminary Q1 2026 Qiagen NV Earnings Call Transcript
Key Points
- Qiagen NV (QGEN) delivered strong profitability with adjusted diluted EPS of $0.54, in line with their outlook despite mixed sales results.
- Four out of five growth pillars achieved or exceeded expectations, with Sample Technologies growing 9% at constant exchange rates (CER).
- QIAsupply delivered double-digit CER sales growth, driven by gains in both consumables and instruments.
- QIAGEN Digital Insights saw solid single-digit CER sales growth, led by clinical applications.
- The company maintained a high level of profitability with an expected adjusted operating income margin of about 27.4%, reflecting continued efficiency gains.
- Sales were below target due to significantly lower QuantiFERON immigration testing demand and caution among US life sciences customers.
- Net sales were $492 million, up 2% on a reported basis but down 1% at CER, missing the outlook for at least 1% growth CER.
- QuantiFERON sales declined 5% CER, primarily due to lower immigration testing demand in the US and Middle East.
- The updated 2026 outlook reflects lower expectations for QuantiFERON and continued caution among US life sciences customers.
- PCR nucleic acid sales declined 13% CER, with significantly lower sales in PCR consumables and the OEM business due to life science funding constraints.
Ladies and gentlemen, thank you for standing by. I am Katie, your call operator. Welcome, and thank you for joining QIAGEN's preliminary Q1 2026 earnings conference call webcast. (Operator Instructions)
At this time, I'd like to introduce your host, Daniel Wendorff, Vice President, Head of Investor Relations at QIAGEN. Please go ahead.
Thank you, Katie, and welcome to our call on our preliminary results for the first quarter of 2026. In light of the update to our 2026 outlook, the pre-announcement was issued in line with German disclosure requirements yesterday evening. We are planning to publish full Q1 2026 results on May 6, 2026. We appreciate your time and interest in QIAGEN. Joining the call today are Thierry Bernard, our Chief Executive Officer, and Roland Sackers, our Chief Financial Officer. Also joining us is Dr. Domenica Martorana from our investor relations team.
As always, today's call is being webcast live and will be archived in the investor relations
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
